Psoriasis Drugs Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type of Treatment, By Mechanism of Action, By Route of Administration, By Region & Competition, 2020-2030F
Global Psoriasis Drugs Market has been valued at USD 21.06 billion in 2024 and is expected to grow at a CAGR of 6.57% through 2030, reaching significant market size by the end of the forecast period. This market is evolving rapidly, driven by the increasing global incidence of psoriasis, ongoing therapeutic advancements, and rising demand for more effective and personalized treatments. Psoriasis is a chronic autoimmune disorder that results in red, inflamed, and scaly skin lesions, affecting millions of people worldwide and significantly impacting quality of life. As awareness and diagnostic capabilities improve, the identification and treatment of psoriasis are becoming more prevalent. The therapeutic landscape is diverse, spanning topical agents, phototherapy, systemic drugs, and biologic therapies. Biologics, in particular, have transformed the treatment paradigm by offering enhanced efficacy and safety. With expanding research, supportive healthcare policies, and increasing patient demand for targeted treatments, the psoriasis drugs market continues to gain momentum across global regions.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 21.06 Billion
Market Size 2030
USD 30.60 Billion
CAGR 2025-2030
6.57%
Fastest Growing Segment
Oral
Largest Market
North America
Key Market Drivers
Increasing Prevalence of Psoriasis
The rising prevalence of psoriasis globally is a key driver for the market. This autoimmune condition, characterized by an overproduction of skin cells, results in painful, itchy, and inflamed patches. The likelihood of developing psoriasis increases with genetic predisposition, which is being amplified as populations grow and awareness of the disease improves. According to a 2025 NIH report, Spain saw a 43.3% increase in psoriasis cases from 2022, growing from 692,317 to 991,832. This significant rise illustrates the expanding patient base. Moreover, modern environmental and lifestyle factors-such as heightened stress, smoking, poor diet, and exposure to pollution-are contributing to the disease's growing incidence. Enhanced diagnostic practices also play a role, allowing more cases, including milder forms, to be correctly identified and treated. Collectively, these factors are intensifying the demand for innovative and effective treatment options.
Key Market Challenges
Limited Understanding of Psoriasis Causes and Triggers
One of the most significant challenges in managing psoriasis is the limited understanding of its exact causes and triggers. As a multifactorial autoimmune disorder, psoriasis involves complex interactions between genetic, environmental, and immune system factors. The variability in genetic markers among patients complicates the development of universal or targeted therapies. Additionally, triggers such as stress, infections, and certain medications vary widely from person to person, making individualized treatment approaches challenging. This lack of clarity in disease etiology hinders the development of more precise treatments and limits the potential for personalized medicine in psoriasis care. It also poses difficulties for clinicians in predicting flare-ups and selecting optimal therapeutic strategies.
A leading trend in the Global Psoriasis Drugs Market is the rising dominance of biologic therapies. These advanced drugs, derived from living organisms, specifically target key immune system pathways responsible for psoriasis, such as cytokines and immune cell receptors. Biologics have shown superior results compared to conventional treatments, offering greater symptom relief and fewer side effects. This has led to a shift in clinical preference, especially for moderate to severe psoriasis cases. Their ability to provide sustained remission has positioned biologics as a mainstay in psoriasis management. The trend is further supported by ongoing drug development and approvals, making these therapies increasingly accessible and expanding the market for targeted biologic solutions.
Key Market Players
Glanbia Plc
Pfizer Inc.
Bayer AG
Amway Corp.
GlaxoSmithKline plc.
Good Health New Zealand
The Nature's Bounty Co.
NOW Foods
Abbott
Herbalife Nutrition
Report Scope:
In this report, the Global Psoriasis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Psoriasis Drugs Market, By Type of Treatment:
Biologic Drugs
Small Molecule Systemic Drugs
Tropical Therapies
Psoriasis Drugs Market, By Mechanism of Action:
TNF Alpha Inhibitors
PDE4 Inhibitors
Interleukin Inhibitors
Others
Psoriasis Drugs Market, By Route of Administration:
Oral
Parenteral
Topical
Psoriasis Drugs Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Psoriasis Drugs Market.
Available Customizations:
Global Psoriasis Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Route of Administrations
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Psoriasis Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies)
5.2.2. By Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, Others)
5.2.3. By Route of Administration (Oral, Parenteral, Topical)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Psoriasis Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type of Treatment
6.2.2. By Mechanism of Action
6.2.3. By Route of Administration
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Psoriasis Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type of Treatment
6.3.1.2.2. By Mechanism of Action
6.3.1.2.3. By Route of Administration
6.3.2. Canada Psoriasis Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type of Treatment
6.3.2.2.2. By Mechanism of Action
6.3.2.2.3. By Route of Administration
6.3.3. Mexico Psoriasis Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type of Treatment
6.3.3.2.2. By Mechanism of Action
6.3.3.2.3. By Route of Administration
7. Europe Psoriasis Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type of Treatment
7.2.2. By Mechanism of Action
7.2.3. By Route of Administration
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Psoriasis Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type of Treatment
7.3.1.2.2. By Mechanism of Action
7.3.1.2.3. By Route of Administration
7.3.2. United Kingdom Psoriasis Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type of Treatment
7.3.2.2.2. By Mechanism of Action
7.3.2.2.3. By Route of Administration
7.3.3. Italy Psoriasis Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Type of Treatment
7.3.3.2.2. By Mechanism of Action
7.3.3.2.3. By Route of Administration
7.3.4. France Psoriasis Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type of Treatment
7.3.4.2.2. By Mechanism of Action
7.3.4.2.3. By Route of Administration
7.3.5. Spain Psoriasis Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type of Treatment
7.3.5.2.2. By Mechanism of Action
7.3.5.2.3. By Route of Administration
8. Asia-Pacific Psoriasis Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type of Treatment
8.2.2. By Mechanism of Action
8.2.3. By Route of Administration
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Psoriasis Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type of Treatment
8.3.1.2.2. By Mechanism of Action
8.3.1.2.3. By Route of Administration
8.3.2. India Psoriasis Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type of Treatment
8.3.2.2.2. By Mechanism of Action
8.3.2.2.3. By Route of Administration
8.3.3. Japan Psoriasis Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type of Treatment
8.3.3.2.2. By Mechanism of Action
8.3.3.2.3. By Route of Administration
8.3.4. South Korea Psoriasis Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type of Treatment
8.3.4.2.2. By Mechanism of Action
8.3.4.2.3. By Route of Administration
8.3.5. Australia Psoriasis Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type of Treatment
8.3.5.2.2. By Mechanism of Action
8.3.5.2.3. By Route of Administration
9. South America Psoriasis Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type of Treatment
9.2.2. By Mechanism of Action
9.2.3. By Route of Administration
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Psoriasis Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type of Treatment
9.3.1.2.2. By Mechanism of Action
9.3.1.2.3. By Route of Administration
9.3.2. Argentina Psoriasis Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type of Treatment
9.3.2.2.2. By Mechanism of Action
9.3.2.2.3. By Route of Administration
9.3.3. Colombia Psoriasis Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type of Treatment
9.3.3.2.2. By Mechanism of Action
9.3.3.2.3. By Route of Administration
10. Middle East and Africa Psoriasis Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type of Treatment
10.2.2. By Mechanism of Action
10.2.3. By Route of Administration
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Psoriasis Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type of Treatment
10.3.1.2.2. By Mechanism of Action
10.3.1.2.3. By Route of Administration
10.3.2. Saudi Arabia Psoriasis Drugs Market Outlook